Literature DB >> 9631841

Incidence of end-stage renal disease in medically treated patients with severe bilateral atherosclerotic renovascular disease.

K Baboolal1, C Evans, R H Moore.   

Abstract

Incidence of end-stage renal disease in medically treated patients with severe bilateral atherosclerotic renovascular disease. Atherosclerotic renovascular disease is an important cause of end-stage renal disease (ESRD). The exact incidence of ESRD and the rate of decline in glomerular filtration rate (GFR) in patients with this condition is unknown. We report the mortality, the rate of decline in renal function, and incidence of ESRD in 51 patients with bilateral atherosclerotic renovascular disease followed-up for a median period of 52 months. None of these patients had undergone any surgical or radiological intervention. Renal function was determined by serial measurements of serum creatinine. Bilateral atherosclerotic renovascular disease was associated with a high mortality rate; the crude mortality rate at 60 months was 45%. Assessment of renal function showed impaired renal function at time of angiography and a nonuniform and variable decline in renal function during the period of observation. The median GFR decreased from 39 mL/min (range, 15 to 80 mL/min) at time of angiography to 31 mL/min (range, 10 to 70 mL/min) and 24 mL/min (range, 10 to 40 mL/min) at 24 and 60 months, respectively (P < 0.05). The calculated mean rate of decline in GFR for all patients was 4 mL/min/yr (range, 1 to 16 mL/min/yr). Over the 5 years, there was a progressive increase in the incidence of ESRD. Of the original 51 patients who underwent angiography, six patients reached ESRD. The crude incidence of ESRD was, therefore, 12%. Patients who reached ESRD were characterized by advanced azotemia at the time of angiography (median GFR, 25 mL/min) and a rapid decline in GFR (8 mL/min) compared with patients who did not reach ESRD during the observation period (median GFR, 43 mL/min and an average rate of decline GFR of 3 mL/min).

Entities:  

Mesh:

Year:  1998        PMID: 9631841     DOI: 10.1053/ajkd.1998.v31.pm9631841

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

Review 1.  Renal failure in atherosclerotic renovascular disease: pathogenesis, diagnosis, and intervention.

Authors:  R G Woolfson
Journal:  Postgrad Med J       Date:  2001-02       Impact factor: 2.401

Review 2.  Atherosclerotic renal artery stenosis: surgery, percutaneous transluminal angioplasty, or medical therapy?

Authors:  P F Plouin; B Guéry; A La Batide Alanore
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

Review 3.  Atherosclerotic-nephropathy: an updated narrative review.

Authors:  Mariadelina Simeoni; Silvio Borrelli; Carlo Garofalo; Giorgio Fuiano; Ciro Esposito; Alessandro Comi; Michele Provenzano
Journal:  J Nephrol       Date:  2020-04-08       Impact factor: 3.902

4.  [Ischemic renal disease and renal artery stenosis].

Authors:  T Lenz
Journal:  Internist (Berl)       Date:  2015-03       Impact factor: 0.743

Review 5.  Cardiovascular morbidity and mortality and renal artery stenosis.

Authors:  William R Colyer; Christopher J Cooper
Journal:  Prog Cardiovasc Dis       Date:  2009 Nov-Dec       Impact factor: 8.194

6.  Reversible dialysis-dependent renal failure due to undiagnosed renovascular disease.

Authors:  R Jha; D Gude; G Narayan; S N Mandal; P C Gupta
Journal:  Indian J Nephrol       Date:  2012-07

7.  Prevalence and risk factors of CKD in Chinese patients with periodontal disease.

Authors:  Kejin Liu; Qinghua Liu; Wei Chen; Mengjun Liang; Wei Luo; Xianfeng Wu; Yiping Ruan; Jie Wang; Ricong Xu; Xiaojiang Zhan; Jianwen Yu; Jiaqing Tan; Xiuqing Dong; Jincai Zhang; Xueqing Yu
Journal:  PLoS One       Date:  2013-08-07       Impact factor: 3.240

8.  Adventitial delivery of lentivirus-shRNA-ADAMTS-1 reduces venous stenosis formation in arteriovenous fistula.

Authors:  Evelyn C Nieves Torres; Binxia Yang; Bhaskar Roy; Rajiv Janardhanan; Akshaar Brahmbhatt; Ed Leof; Debabrata Mukhopadhyay; Sanjay Misra
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.